Engineered T-Cells take on blood cancers in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: FOR TREATMENT: * Recurrent low or intermediate grade B-cell lymphoma or B-CLL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory intermediate B cell lymphoma with a treatment plan that will include high dose therapy and autologous stem cell transplantation. * CD19-positive tumor * EBV seropositivity (in patient and donor, as applicable) * Recovered from the acute toxic effects of all prior chemotherapy at least a week before entering this study. * Not be currently receiving any investigational agents or have not received any tumor vaccines within the previous six weeks. * No treatment with rituximab within the previous 8 weeks. * ANC \> 500, Hgb \> 8.0\* * Bilirubin less than 3 times the upper limit of normal\* * AST less than 5 times the upper limit of normal\* * Serum creatinine less than 3 times upper limit of normal\* * Pulse oximetry of \> 90% on room air\* * Adequate pulmonary function with FEV1, FVC and DLCO \>35%\* of expected corrected for hemoglobin * Karnofsky or Lansky score of \> 60%. * Available autologous or syngeneic transduced EBV-specific cytotoxic T lymphocytes and peripheral blood T-cells with 15% or greater expression of CD19CAR determined by flow-cytometry. * Patients or legal guardians must understand and sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form. * Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded. The male partner should use a condom. EXCLUSION CRITERIA: * History of hypersensitivity reactions to murine protein-containing products. * Pregnant or lactating. * Tumor in a location where enlargement could cause airway obstruction. * Active infection with HIV, HBV, HCV or CMV.